News

Deal Announcements

Cytovance Biologics Secures Venture Capital Debt

Wednesday, October 29, 2014 5:30:00 AM PDT | VentureDeal
   Oklahoma City, Oklahoma  --  Biotechnology company Cytovance Biologics has raised $20 million in venture capital debt financing.

Cytovance says that it was "founded to help biopharmaceutical companies move recombinant protein and antibody products rapidly from the bench through clinical development."

Monroe Capital made the debt facility.

Cytovance said it will use the funds to continue to grow its operations.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1